MedInCell Shares Drop 3.72%, Falling Below Key Moving Averages
The Montpellier-based biotech company's stock significantly declined this Tuesday, moving against the trend of a CAC 40 that rose by 1.33% during the session. MedInCell fell by 3.72% to €22.24, after closing at €23.10 before the long Easter weekend. This decline is part of a challenging quarter for the stock, which has seen a decrease of more than 9% over three months.
Current Trading Position
In mid-morning trading, MedInCell is priced at €22.24, now below its 50-day moving average of €23.22 and its 200-day average of €23.52. This double dip below these medium and long-term benchmarks indicates a selling pressure that has been mounting over the past few weeks, with the stock having lost more than 9% since the beginning of January. However, the price remains above its 20-day moving average of €21.62, which acts as the first cushion.
The RSI indicator is positioned at 53, which is in the neutral zone, indicating neither overbought nor oversold conditions. The Bollinger Bands frame the price between an upper limit of €23.41 and a lower limit of €19.82: the stock is in the upper half of this channel. The technical support identified at €20.24 is the next threshold to watch if the decline continues, while resistance is found at €24.94.
Upcoming Financial Milestones
Today's decline comes as the company, which specializes in long-duration injection technologies, approaches significant deadlines. The publication of the annual results for the fiscal year 2025-2026 is scheduled for June 16th, an event expected to provide greater visibility into the financial trajectory of the group. The general meeting will follow on September 10th, before the announcement of the results for the first half of 2026-2027 expected on December 8th.
The stock performance of MedInCell remains mixed depending on the time horizon considered: while the stock has increased by more than 66% over the past year, it has fallen by 9% over the last quarter. The volatility measured over a month is 14.46%, and the beta of 0.08 indicates a low correlation with general market movements. Among comparable pharmaceutical sector stocks, Sanofi is up 0.85% in today's session, while UCB has dropped 1.36%. MedInCell's decline thus appears more pronounced than the sector trend observed this morning on European markets.
